We are live on
!
Find out more
FRM
Fox Run Management Portfolio holdings
AUM
$603M
1-Year Est. Return
32%
This Fund
S&P 500
This Quarter
Est. Return
+0.14%
1 Year Est. Return
+32%
3 Year Est. Return
+63.99%
5 Year Est. Return
+46.87%
10 Year Est. Return
+296.03%
AUM
$150M
AUM Growth
+$20.3M
(+16%)
Cap. Flow
+$15.7M
Cap. Flow
% of AUM
10.5%
Top 10 Holdings %
Top 10 Hldgs %
9.04%
Holding
664
New
292
Increased
44
Reduced
53
Closed
273
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$1.11M |
| 2 |
CELG
Celgene Corp
CELG
|
+$1.11M |
| 3 |
Nike
NKE
|
+$1.03M |
| 4 |
PAY
Verifone Systems Inc
PAY
|
+$959K |
| 5 |
MON
Monsanto Co
MON
|
+$894K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.43M |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$2.19M |
| 3 |
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
|
+$1.41M |
| 4 |
Enterprise Products Partners
EPD
|
+$1.02M |
| 5 |
Magna International
MGA
|
+$933K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.72% |
| 2 | Consumer Discretionary | 15.05% |
| 3 | Technology | 12.69% |
| 4 | Industrials | 11.68% |
| 5 | Financials | 9.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MNDT
151
DELISTED
Mandiant, Inc. Common Stock
MNDT
| $376K | 0.25% |
+20,900
| New | +$341K |
|
|
PACW
152
DELISTED
PacWest Bancorp
PACW
| $375K | 0.25% |
10,100
-100
| -1% | -$3.54K |
|
153
BP
BP
$113B
| $374K | 0.25% |
+14,737
| New | +$372K |
|
|
SYNH
154
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $371K | 0.25% |
+9,000
| New | +$371K |
|
155
Skywest
SKYW
$3.85B
| $370K | 0.25% |
+18,500
| New | +$313K |
|
156
Green Dot
GDOT
$760M
| $368K | 0.25% |
+16,000
| New | +$311K |
|
157
Lincoln National
LNC
$8.71B
| $368K | 0.25% |
+9,400
| New | +$367K |
|
158
Wintrust Financial
WTFC
$10.4B
| $368K | 0.25% |
+8,300
| New | +$356K |
|
159
W.P. Carey
WPC
$16B
| $367K | 0.25% |
6,024
-1,429
| -19% | -$81.2K |
|
160
CME Group
CME
$101B
| $365K | 0.24% |
+3,800
| New | +$346K |
|
161
Bristol-Myers Squibb
BMY
$136B
| $364K | 0.24% |
+5,700
| New | +$359K |
|
|
ESRX
162
DELISTED
Express Scripts Holding Company
ESRX
| $364K | 0.24% |
+5,300
| New | +$381K |
|
163
Silgan Holdings
SLGN
$4.35B
| $362K | 0.24% |
+13,600
| New | +$353K |
|
|
BLUE
164
DELISTED
bluebird bio
BLUE
| $361K | 0.24% |
+656
| New | +$403K |
|
165
Plains All American Pipeline
PAA
$18.1B
| $361K | 0.24% |
+17,200
| New | +$362K |
|
|
QTS
166
DELISTED
QTS REALTY TRUST, INC.
QTS
| $360K | 0.24% |
+7,600
| New | +$339K |
|
|
SWFT
167
DELISTED
Swift Transportation Company
SWFT
| $360K | 0.24% |
+19,300
| New | +$313K |
|
|
AM
168
DELISTED
ANTERO MIDSTREAM PARTNERS LP
AM
| $360K | 0.24% |
16,301
-6,699
| -29% | -$143K |
|
169
First American
FAF
$7.43B
| $358K | 0.24% |
+9,400
| New | +$335K |
|
170
MGM Resorts International
MGM
$10.4B
| $358K | 0.24% |
16,700
-1,500
| -8% | -$29.6K |
|
171
CDW
CDW
$19.1B
| $357K | 0.24% |
+8,600
| New | +$335K |
|
|
PX
172
DELISTED
Praxair Inc
PX
| $355K | 0.24% |
3,100
+300
| +11% | +$31.3K |
|
173
Zurn Elkay Water Solutions
ZWS
$7.9B
| $354K | 0.24% |
+36,330
| New | +$308K |
|
174
GE Aerospace
GE
$350B
| $353K | 0.24% |
+2,316
| New | +$327K |
|
|
HW
175
DELISTED
Headwaters Inc
HW
| $353K | 0.24% |
+17,800
| New | +$298K |
|
Similar funds
PCTC
EHI
VCP
OPWM
F1I
AMG
MAM
SCM
Fox Run Management's Q1 2016 Portfolio in Review
As of Q1 2016, Fox Run Management held 664 positions worth $150M, up 16% from $129M the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Fox Run Management deployed $15.7M of net new capital in Q1 2016, opening 292 new positions and adding to 44 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 2,700 shares worth $973K.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 10% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $2.43M trimmed.
- Fox Run Management's largest Q1 2016 buy was Regeneron Pharmaceuticals: 2,700 shares worth $973K.
- Fox Run Management added most to Hologic in Q1 2016, an estimated $823K increase.
- Fox Run Management's biggest Q1 2016 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $2.43M.
- Fox Run Management fully exited Enterprise Products Partners in Q1 2016, selling an estimated $1.02M.
- Fox Run Management's ten largest holdings make up 9% of its $150M portfolio in Q1 2016.
- Fox Run Management opened 292 new positions and closed 273 in Q1 2016.
- Fox Run Management's portfolio value rose 16% quarter-over-quarter to $150M.
Based on Fox Run Management's 13F filing for Q1 2016, filed 18 Apr 2016.